Endogenous protein C has a protective role during Gram-negative pneumosepsis (melioidosis)

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 2, 2013, Pages 282-292

  Kager, L M ^a   Wiersinga, W J ^a   Roelofs, J J ^a   Meijers, J C M ^a   Zeerleder, S S ^a   Esmon, C T ^b   Van't Veer, C ^a   Van der Poll, T ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Activated protein C; Coagulation; Lung inflammation; Melioidosis; Sepsis

Indexed keywords

5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; ACTIVATED PROTEIN C; ENZYME ANTIBODY; MAPC 1591; MPC 1609; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BACTERIAL GROWTH; BLOOD CLOTTING; CELL PROTECTION; CONTROLLED STUDY; FEMALE; GRAM NEGATIVE SEPSIS; INFLAMMATION; MELIOIDOSIS; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN FUNCTION; SURVIVAL;

ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIAL LOAD; BLOOD COAGULATION; BURKHOLDERIA PSEUDOMALLEI; CYTOKINES; CYTOPROTECTION; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION; INFLAMMATION MEDIATORS; LIVER; LUNG; LYSOPHOSPHOLIPIDS; MELIOIDOSIS; MICE; MICE, INBRED C57BL; OXADIAZOLES; PROTEIN C; RECEPTOR, PAR-1; SEPSIS; SIGNAL TRANSDUCTION; SPHINGOSINE; THIOPHENES; TIME FACTORS;

EID: 84873543108     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12094     Document Type: Article

References (38)

1. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32(Suppl 1): 49-60.
2. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-72.
3. Danese S, Vetrano S, Zhang L, Poplis VA, Castellino FJ. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010; 115: 1121-30.
4. Sammani S, Moreno-Vinasco L, Mirzapoiazova T, Singleton PA, Chiang ET, Evenoski CL, Wang T, Mathew B, Husain A, Moitra J, Sun X, Nunez L, Jacobson JR, Dudek SM, Natarajan V, Garcia JG. Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung. Am J Respir Cell Mol Biol 2010; 43: 394-402.
5. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 2011; 11: 403-15.
6. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105: 3178-84.
7. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005; 280: 17286-93.
8. McVerry BJ, Peng X, Hassoun PM, Sammani S, Simon BA, Garcia JG. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med 2004; 170: 987-93.
9. Peng X, Hassoun PM, Sammani S, McVerry BJ, Burne MJ, Rabb H, Pearse D, Tuder RM, Garcia JG. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 2004; 169: 1245-51.
10. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT. Extracellular histones are major mediators of death in sepsis. Nat Med 2009; 15: 1318-21.
11. Shaw AD, Vail GM, Haney DJ, Xie J, Williams MD. Severe protein C deficiency is associated with organ dysfunction in patients with severe sepsis. J Crit Care 2011; 26: 539-45.
12. Macias WL, Nelson DR. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 2004; 32: S223-8.
13. Fisher CJ Jr, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000; 28: S49-56.
14. Liaw PC, Esmon CT, Kahnamoui K, Schmidt S, Kahnamoui S, Ferrell G, Beaudin S, Julian JA, Weitz JI, Crowther M, Loeb M, Cook D. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2004; 104: 3958-64.
15. Levi M, Dorffler-Melly J, Reitsma P, Buller H, Florquin S, van der Poll T, Carmeliet P. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood 2003; 101: 4823-7.
16. Lay AJ, Donahue D, Tsai MJ, Castellino FJ. Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood 2007; 109: 1984-91.
17. Schouten M, van 't Veer C, Levi M, Esmon CT, van der Poll T. Endogenous protein C inhibits activation of coagulation and transiently lowers bacterial outgrowth in murine Escherichia coli peritonitis. J Thromb Haemost 2011; 9: 1072-5.
18. Schouten M, de Boer JD, van der Sluijs KF, Roelofs JJ, van't Veer C, Levi M, Esmon CT, van der Poll T. Impact of endogenous protein C on pulmonary coagulation and injury during lethal H1N1 influenza in mice. Am J Respir Cell Mol Biol 2011; 45: 789-94.
19. Xu J, Ji Y, Zhang X, Drake M, Esmon CT. Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock. J Thromb Haemost 2009; 7: 851-6.
20. Kager LM, Wiersinga WJ, Roelofs JJ, Meijers JC, Levi M, van 't Veer C, van der Poll T. Plasminogen activator inhibitor type I contributes to protective immunity during experimental Gram-negative sepsis (melioidosis). J Thromb Haemost 2011; 9: 2020-8.
21. Kager LM, Wiersinga WJ, Roelofs JJ, Meijers JC, Levi M, van 't Veer C, van der Poll T. Endogenous tissue-type plasminogen activator impairs host defense during severe experimental gram-negative sepsis (melioidosis). Crit Care Med 2012; 40: 2168-75.
22. Wiersinga WJ, Wieland CW, Dessing MC, Chantratita N, Cheng AC, Limmathurotsakul D, Chierakul W, Leendertse M, Florquin S, de Vos AF, White N, Dondorp AM, Day NP, Peacock SJ, van der Poll T. Toll-like receptor 2 impairs host defense in gram-negative sepsis caused by Burkholderia pseudomallei (Melioidosis). PLoS Med 2007; 4: e248.
23. Meumann EM, Cheng AC, Ward L, Currie BJ. Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature. Clin Infect Dis 2012; 54: 362-9.
24. White NJ. Melioidosis. Lancet 2003; 361: 1715-22.
25. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 2006; 4: 272-82.
26. Wiersinga WJ, Meijers JC, Levi M, van 't Veer C, Day NP, Peacock SJ, van der Poll T. Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis. J Thromb Haemost 2008; 6: 32-9.
27. LaRosa SP, Opal SM, Utterback B, Yan SC, Helterbrand J, Simpson AJ, Chaowagul W, White NJ, Fisher CJ Jr. Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei. Int J Infect Dis 2006; 10: 25-31.
28. van Sluis GL, Niers TM, Esmon CT, Tigchelaar W, Richel DJ, Buller HR, van Noorden CJ, Spek CA. Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement. Blood 2009; 114: 1968-73.
29. Awad AS, Ye H, Huang L, Li L, Foss FW Jr, Macdonald TL, Lynch KR, Okusa MD. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol 2006; 290: F1516-24.
30. Zeerleder S, Zwart B, te Velthuis H, Manoe R, Bulder I, Rensink I, Aarden LA. A plasma nucleosome releasing factor (NRF) with serine protease activity is instrumental in removal of nucleosomes from secondary necrotic cells. FEBS Lett 2007; 581: 5382-8.
31. van der Windt GJ, Schouten M, Zeerleder S, Florquin S, van der Poll T. CD44 is protective during hyperoxia-induced lung injury. Am J Respir Cell Mol Biol 2011; 44: 377-83.
32. Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 2007; 110: 3909-16.
33. Kerschen E, Hernandez I, Zogg M, Jia S, Hessner MJ, Fernandez JA, Griffin JH, Huettner CS, Castellino FJ, Weiler H. Activated protein C targets CD8 + dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest 2010; 120: 3167-78.
34. Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveld AB, Caliezi C, van Nieuwenhuijze AE, van Mierlo GJ, Eerenberg AJ, Lammle B, Hack CE. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 2003; 31: 1947-51.
35. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366: 2055-64.
36. Levi M, van der Poll T. Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 2007; 11(Suppl 5): S3.
37. Ruf W. New players in the sepsis-protective activated protein C pathway. J Clin Invest 2010; 120: 3084-7.
38. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, Castellino FJ, Mackman N, Griffin JH, Weiler H. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204: 2439-48.